Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors
暂无分享,去创建一个
Silvio C. E. Tosatto | Giovanni Minervini | Federica Quaglia | Francesco Tabaro | S. Tosatto | G. Minervini | Federica Quaglia | Francesco Tabaro | F. Quaglia
[1] R. Gatti,et al. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. , 2005, Haematologica.
[2] S. Signoretti,et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.
[3] B. Raught,et al. Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling* , 2016, The Journal of Biological Chemistry.
[4] W. Kaelin,et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.
[5] Claudio R. Thoma,et al. Priming-Dependent Phosphorylation and Regulation of the Tumor Suppressor pVHL by Glycogen Synthase Kinase 3 , 2006, Molecular and Cellular Biology.
[6] Damian Szklarczyk,et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..
[7] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[8] Jun O. Liu,et al. Nur77 Activated by Hypoxia-Inducible Factor-1α Overproduces Proopiomelanocortin in von Hippel-Lindau-Mutated Renal Cell Carcinoma , 2004, Cancer Research.
[9] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[10] David W. Ritchie,et al. Ultra-fast FFT protein docking on graphics processors , 2010, Bioinform..
[11] H. Youn,et al. The Positive Regulation of p53 by the Tumor Suppressor VHL , 2006, Cell cycle.
[12] K. Huntoon,et al. Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. , 2013, Cell reports.
[13] Silvio C. E. Tosatto,et al. MobiDB 3.0: more annotations for intrinsic disorder, conformational diversity and interactions in proteins , 2017, Nucleic Acids Res..
[14] J. Cheng,et al. pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner , 2016, Science.
[15] J. Pouysségur,et al. HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.
[16] T. Kietzmann,et al. Glycogen Synthase Kinase 3 Phosphorylates Hypoxia-Inducible Factor 1α and Mediates Its Destabilization in a VHL-Independent Manner , 2007, Molecular and Cellular Biology.
[17] J. Patard,et al. Identification of pVHL as a Novel Substrate for Aurora-A in Clear Cell Renal Cell Carcinoma (ccRCC) , 2013, PloS one.
[18] M. V. Panchenko,et al. Jade-1, a candidate renal tumor suppressor that promotes apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] F. Sánchez‐Madrid,et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. , 2002, Cancer research.
[20] Anushya Muruganujan,et al. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..
[21] Vittorio Scarano,et al. CONSRANK: a server for the analysis, comparison and ranking of docking models based on inter-residue contacts , 2015, Bioinform..
[22] J. Klco,et al. pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development , 2004, Molecular and Cellular Biology.
[23] Silvio C. E. Tosatto,et al. The RING 2.0 web server for high quality residue interaction networks , 2016, Nucleic Acids Res..
[24] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[25] B. Ebert,et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. , 2007, Molecular cell.
[26] W. Lim,et al. Systematic Functional Prioritization of Protein Posttranslational Modifications , 2012, Cell.
[27] J. Pelletier,et al. The von Hippel-Lindau Protein pVHL Inhibits Ribosome Biogenesis and Protein Synthesis* , 2013, The Journal of Biological Chemistry.
[28] Lars J. Jensen,et al. Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells , 2016, Science Signaling.
[29] A. V. D. van den Ouweland,et al. Genetic analysis of von Hippel‐Lindau disease , 2010, Human mutation.
[30] Sebastian A. Wagner,et al. A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles* , 2011, Molecular & Cellular Proteomics.
[31] M. Ohh,et al. The multifaceted von Hippel–Lindau tumour suppressor protein , 2014, FEBS letters.
[32] S. Weintraub,et al. Proteomic dissection of the von Hippel-Lindau (VHL) interactome. , 2011, Journal of proteome research.
[33] S. Tosatto,et al. Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein , 2015, Scientific Reports.
[34] S. Tosatto,et al. Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health. , 2015, Biochimie.
[35] E. Cho,et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.
[36] M. Ohh,et al. NEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL , 2008, EMBO reports.
[37] Y. Xiong,et al. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. , 2015, Structure.
[38] R. Conaway,et al. von Hippel–Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] Silvio C. E. Tosatto,et al. VHLdb: A database of von Hippel-Lindau protein interactors and mutations , 2016, Scientific Reports.
[40] Silvio C. E. Tosatto,et al. Adding structural information to the von Hippel–Lindau (VHL) tumor suppressor interaction network , 2009, FEBS letters.
[41] Gary D. Bader,et al. An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.
[42] E. Voest,et al. Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain* , 2005, Journal of Biological Chemistry.
[43] E. Robertson,et al. Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization , 2010, PloS one.
[44] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Gygi,et al. The Conserved Bardet-Biedl Syndrome Proteins Assemble a Coat that Traffics Membrane Proteins to Cilia , 2010, Cell.
[46] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[47] Robert S. Freeman,et al. Oxygen-Regulated β2-Adrenergic Receptor Hydroxylation by EGLN3 and Ubiquitylation by pVHL , 2009, Science Signaling.
[48] William Y. Kim,et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia , 2011, Nature Medicine.
[49] K. Hemminki,et al. Familial cancers in a nationwide family cancer database: age distribution and prevalence. , 1999, European journal of cancer.
[50] Yigong Shi. Faculty Opinions recommendation of Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. , 2002 .
[51] G. Semenza,et al. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .
[52] Andrew N Freedman,et al. Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey , 2010, Genetics in Medicine.
[53] J. Vandekerckhove,et al. Prefoldin, a Chaperone that Delivers Unfolded Proteins to Cytosolic Chaperonin , 1998, Cell.
[54] D. Pignatelli,et al. Von Hippel–Lindau disease: a single gene, several hereditary tumors , 2017, Journal of Endocrinological Investigation.
[55] E. Cho,et al. Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation. , 2008, Experimental & molecular medicine.
[56] W. Krek,et al. pVHL: A Multipurpose Adaptor Protein , 2008, Science Signaling.
[57] D. Orth,et al. Proopiomelanocortin gene expression in a pheochromocytoma using upstream transcription initiation sites. , 1988, Biochemical and biophysical research communications.
[58] W. Krek,et al. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. , 2004, Trends in molecular medicine.
[59] P. Cohen,et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.
[60] E. Robertson,et al. Hypoxia Inactivates the VHL Tumor Suppressor through PIASy-Mediated SUMO Modification , 2010, PloS one.
[61] D. Seldin,et al. Jade-1 inhibits Wnt signaling by ubiquitinating β-catenin and mediates Wnt pathway inhibition by pVHL , 2008, Nature Cell Biology.
[62] J. Bruder,et al. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. , 1999, Biochemical and biophysical research communications.
[63] Emmanuel Ampofo,et al. Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. , 2010, The international journal of biochemistry & cell biology.
[64] S. Gygi,et al. Regulation of Cellular Levels of Sprouty2 Protein by Prolyl Hydroxylase Domain and von Hippel-Lindau Proteins* , 2011, The Journal of Biological Chemistry.
[65] M. Ohh,et al. The HIF and other quandaries in VHL disease , 2018, Oncogene.
[66] E. Messing,et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel—Lindau protein , 2003, The EMBO journal.
[67] Andrea Gazzo,et al. PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update , 2017, Nucleic Acids Res..
[68] P. Heikkilä,et al. HuR in pheochromocytomas and paragangliomas – overexpression in verified malignant tumors , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[69] C. Heinlein,et al. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. , 2002, Molecular endocrinology.
[70] E. Maher,et al. VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.
[71] R. Burk,et al. Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[72] E. Cho,et al. Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation , 2011, Cell cycle.
[73] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[74] Olga G. Troyanskaya,et al. GIANT 2.0: genome-scale integrated analysis of gene networks in tissues , 2018, Nucleic Acids Res..
[75] Wei Zhang,et al. The von hippel-lindau protein suppresses androgen receptor activity. , 2014, Molecular endocrinology.
[76] William Y. Kim,et al. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL , 2011, Journal of cellular and molecular medicine.
[77] P. Ratcliffe,et al. Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor* , 2007, Journal of Biological Chemistry.
[78] A. Zharkikh,et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.
[79] Fernand Labrie,et al. Comparison of crystal structures of human androgen receptor ligand‐binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity , 2006, Protein science : a publication of the Protein Society.
[80] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[81] A. Pause,et al. Collagen matrix assembly is driven by the interaction of von Hippel–Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 , 2008, Oncogene.
[82] David S. Goodsell,et al. The RCSB protein data bank: integrative view of protein, gene and 3D structural information , 2016, Nucleic Acids Res..
[83] D. Mukhopadhyay,et al. Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma , 2005, Oncogene.
[84] V. Venkataramanan,et al. The deubiquitinases USP33 and USP20 coordinate β2 adrenergic receptor recycling and resensitization , 2009, The EMBO journal.
[85] Manfred Auer,et al. The x-ray crystal structure of the first RNA recognition motif and site-directed mutagenesis suggest a possible HuR redox sensing mechanism. , 2010, Journal of molecular biology.
[86] E. Cho,et al. Nur77 upregulates HIF-α by inhibiting pVHL-mediated degradation , 2008, Experimental & Molecular Medicine.
[87] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[88] K. Dyer,et al. Hsp70RY: further characterization of a novel member of the hsp70 protein family. , 1994, Biochemical and biophysical research communications.
[89] A. Tabarin,et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.
[90] S. Tosatto,et al. Design and Analysis of a Petri Net Model of the Von Hippel-Lindau (VHL) Tumor Suppressor Interaction Network , 2014, PloS one.
[91] C. Stiller. Epidemiology and genetics of childhood cancer , 2004, Oncogene.
[92] Silvio C. E. Tosatto,et al. FELLS: fast estimator of latent local structure , 2017, Bioinform..
[93] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[94] Peter L. Choyke,et al. Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease , 2016, Nature Reviews Clinical Oncology.
[95] Svetlana V. Harbaugh,et al. The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress , 2008, Molecular and Cellular Biology.
[96] G. Mills,et al. Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function , 2016, Oncogene.